ADARx Pharmaceuticals, Inc. ADRX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 258.65% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 258.65% | -- | |||
| Cost of Revenue | 44.90% | 82.91% | |||
| Gross Profit | -42.26% | -66.31% | |||
| SG&A Expenses | 38.57% | 12.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.63% | 63.22% | |||
| Operating Income | -41.52% | -51.25% | |||
| Income Before Tax | -42.37% | -45.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -42.37% | -45.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -42.37% | -45.76% | |||
| EBIT | -41.52% | -51.25% | |||
| EBITDA | -41.65% | -51.23% | |||
| EPS Basic | -42.80% | -45.87% | |||
| Normalized Basic EPS | -42.79% | -45.87% | |||
| EPS Diluted | -42.80% | -45.87% | |||
| Normalized Diluted EPS | -42.79% | -45.87% | |||
| Average Basic Shares Outstanding | -0.30% | -0.08% | |||
| Average Diluted Shares Outstanding | -0.30% | -0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||